Preston Klassen

2009 - Orexigen Therapeutics

In 2009, Preston Klassen earned a total compensation of $1.2M as Head of Global Contrave Program and Senior Vice President, Product Development at Orexigen Therapeutics.

Compensation breakdown

Bonus$35,000
Option Awards$875,600
Salary$38,333
Other$225,020
Total$1,173,953

Klassen received $875.6K in option awards, accounting for 75% of the total pay in 2009.

Klassen also received $35K in bonus, $38.3K in salary and $225K in other compensation.

Rankings

In 2009, Preston Klassen's compensation ranked 3,911th out of 9,885 executives tracked by ExecPay. In other words, Klassen earned more than 60.4% of executives.

ClassificationRankingPercentile
All
3,911
out of 9,885
60th
Division
Manufacturing
1,387
out of 3,690
62nd
Major group
Chemicals And Allied Products
263
out of 866
70th
Industry group
Drugs
153
out of 638
76th
Industry
Pharmaceutical Preparations
120
out of 446
73rd
Source: SEC filing on April 27, 2012.

Klassen's colleagues

We found seven more compensation records of executives who worked with Preston Klassen at Orexigen Therapeutics in 2009.

2009

Michael Narachi

Orexigen Therapeutics

Chief Executive Officer

2009

Mark Booth

Orexigen Therapeutics

Chief Commercial Officer

2009

Dawn Viveash

Orexigen Therapeutics

Senior Vice President, Regulatory Affairs

2009

Graham Cooper

Orexigen Therapeutics

Chief Financial Officer

2009

Joseph Hagan

Orexigen Therapeutics

Chief Business Officer

2009

Heather Turner

Orexigen Therapeutics

General Counsel

2009

Eckard Weber

Orexigen Therapeutics

Chief Executive Officer

News

In-depth

You may also like